Patent Assignment
Reel/Frame 065177/0196
Security Interest
Recorded: 2023-10-06
Pages: 114
Assignor
AMICUS THERAPEUTICS, INC.
Executed: 2023-10-05
Assignee
WILMINGTON TRUST, NATIONAL ASSOCIATION
50 SOUTH SIXTH STREET, SUITE 1290, MINNEAPOLIS, MINNESOTA, 55402
Covered Properties
(377)
Assays for diagnosing and evaluating treatment options for Fabry disease
Application:
60/853,631 →
Diagnostic assay for fabry disease
Application:
60/801,089 →
Methods for Treatment of Fabry Disease
Application:
17/665,969 →
Publication:
US US20220160690A1
Assays for Diagnosing and Evaluating Treatment Options for Fabry Disease
Application:
12/966,904 →
Publication:
US US20110104727A1
Method For The Treatment Of Fabry Disease Using Pharmacological Chaperones
Application:
60/909,185 →
Method for the Treatment of Fabry Disease Using Pharmacological Chaperones
Application:
12/594,124 →
Publication:
US US20100113517A1
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Application:
61/028,141 →
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Application:
61/035,684 →
Method To Predict Response To Pharamacological Chaperone Treatment Of Diseases
Application:
61/093,631 →
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Application:
61/113,496 →
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Application:
15/268,662 →
Publication:
US US20170003301A1
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Application:
17/079,859 →
Publication:
US US20250082621A9
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Application:
12/860,611 →
Publication:
US US20110152319A1
Treatment of Fabry Disease in Ert-NaïVe and Ert-Experienced Patientn
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Application:
17/346,994 →
Publication:
US US20220031681A1
Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Fabry Disease
Application:
61/451,798 →
Dosing Regimens for the Treatment of Fabry Disease
Application:
61/596,165 →
Dosing Regimens for the Treatment of Fabry Disease
Application:
61/578,201 →
Dosing Regimens for the Treatment of Fabry Disease
Application:
14/004,335 →
Publication:
US US20140219986A1
Dosing Regimens For The Treatment Of Fabry Disease
Application:
15/782,431 →
Publication:
US US20180153999A1
Dosing Regimens For The Treatment Of Fabry Disease
Application:
16/806,404 →
Publication:
US US20200268890A1
Dosing Regimens For The Treatment Of Fabry Disease
Application:
18/222,745 →
Publication:
US US20240115708A1
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Application:
62/311,511 →
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Application:
62/444,578 →
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Application:
62/524,692 →
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Application:
17/838,741 →
Publication:
US US20230158123A1
Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
Application:
16/642,620 →
Publication:
US US20200222377A1
Methods of Enhancing and/or Stabilizing Cardiac Function in Patients with Fabry Disease
Application:
62/550,984 →
Methods Of Stabilizing Renal Function In Fabry Patients Having Renal Impairment
Application:
62/512,458 →
Methods Of Treating Fabry Patients Having Renal Impairment
Application:
62/626,953 →
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Treatment Of Patients With Classic Fabry Disease
Application:
16/967,824 →
Publication:
US US20210038579A1
Treatment Of Patients With Classic Fabry Disease
Application:
62/626,992 →
Methods Of Treating Fabry Disease In Pregnant Patients
Application:
62/626,955 →
Use Of Migalastat For Treating Fabry Disease In Pregnant Patients
Application:
17/838,820 →
Publication:
US US20220387462A1
Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
62/719,962 →
Use of Migalostat in Reducing the Risk of Cerebrovascular Event in Patients with Fabry Disease
Application:
17/424,979 →
Publication:
US US20220087993A1
Methods Of Treating Fabry Disease In Patients Having Renal Impairment
Application:
17/618,277 →
Publication:
US US20220313670A1
Methods Of Treating Fabry Disease In Patients Having Renal Impairment
Application:
62/859,904 →
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Methods Of Treating Fabry Disease
Application:
17/172,846 →
Publication:
US US20210251972A1
Methods Of Treating Fabry Disease
Application:
62/972,392 →
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
17/909,450 →
Publication:
US US20230136297A1
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
62/986,297 →
Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
Application:
63/126,264 →
Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
Methods of Treating Fabry Disease
Application:
63/220,816 →
Methods of Improving the Pharmacokinetics of Migalastat
Application:
18/315,928 →
Publication:
US US20240197706A1
Methods of Improving the Pharmacokinetics of Migalastat
Application:
63/432,235 →
Method for treating pompe disease
Application:
60/682,241 →
Method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
Application:
60/729,329 →
Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives
Application:
14/876,018 →
Publication:
US US20160051528A1
Dosing Regimens for the Treatment of Pompe Disease
Application:
14/398,210 →
Publication:
US US20150086530A1
Dosing Regimens for the Treatment of Pompe Disease
Application:
61/642,311 →
Dosing Regimens for the Treatment of Pompe Disease
Application:
61/664,011 →
Dosing Regimens for the Treatment of Pompe Disease
Application:
61/697,179 →
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Application:
61/607,920 →
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Application:
61/750,718 →
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Highly Potent Modified Acid Alpha-Glucosidase and Method of Making and Using It
Application:
62/057,842 →
Highly Potent Modified Acid Alpha-Glucosidase and Method of Making and Using It
Application:
62/057,847 →
Highly Potent Modified Acid Alpha-Glucosidase and Method of Making and Using It
Application:
62/112,463 →
Highly Potent Modified Acid Alpha-Glucosidase and Method of Making and Using It
Application:
62/135,345 →
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Application:
18/111,321 →
Publication:
US US20230203465A1
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
15/394,135 →
Publication:
US US20170189497A1
Augmented Acid Alpha-Glucoside for the Treatment of Pompe Disease
Application:
62/272,890 →
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
62/300,479 →
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
62/315,412 →
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
62/402,454 →
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
62/428,867 →
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
62/431,791 →
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Method for Selection of High M6P Recombinant Proteins
Application:
62/315,400 →
Method for Selection of High M6P Recombinant Proteins
Application:
62/457,584 →
Method For Selection Of High M6P Recombinant Proteins
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Application:
62/315,436 →
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Application:
62/457,588 →
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Recombinant Human Acid Alpha-Glucosidase
Recombinant Human Acid Alpha-Glucosidase
Application:
62/564,083 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/567,334 →
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
62/506,561 →
Method for Selection of High M6P Recombinant Proteins
Application:
62/506,569 →
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Application:
62/506,574 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/618,021 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/624,638 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/660,758 →
Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
Application:
18/276,954 →
Publication:
US US20240197839A1
Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
Application:
63/148,596 →
Methods for Treating Pompe Disease
Application:
63/338,601 →
Methods for Treating Pompe Disease
Application:
63/399,498 →
Methods for Treating Pompe Disease
Application:
63/399,491 →
Methods for Treating Pompe Disease
Application:
63/404,475 →
Methods for Treating Pompe Disease
Application:
63/414,897 →
Methods for Treating Pompe Disease
Application:
63/428,970 →
Methods for Treating Pompe Disease
Application:
63/431,920 →
Methods for Treating Pompe Disease
Application:
63/434,791 →
Methods for Treating Pompe Disease
Application:
63/447,222 →
Methods for Treating Late Onset Pompe Disease in Pediatric Patients
Application:
63/429,966 →
Methods for Treating Infantile-Onset Pompe Disease in Pediatric Patients
Application:
63/429,969 →
Methods for Treating Infantile-Onset Pompe Disease in Pediatric Patients
Application:
63/449,810 →
Gene Therapy Constructs for the Treatment of Pompe Disease
Application:
63/438,960 →
Drug Package
Patent:
1,082,532 →
Application:
29/801,766 →
CDKL5 Expression Variants and CDKL5 Fusion Proteins
Application:
16/768,511 →
Publication:
US US20200299654A1
CDKL5 Fusion Proteins
Application:
62/592,944 →
Recombinant Acid Alpha-Glucosidase
Application:
62/529,300 →
Gene Therapy Constructs and Methods of Use
Application:
62/664,741 →
Gene Therapy Constructs and Methods of Use
Application:
62/688,640 →
Gene Therapy Constructs and Methods of Use
Application:
62/744,068 →
Gene Therapy Constructs and Methods of Use
Application:
18/053,160 →
Publication:
US US20230233711A1
Alpha-Galactosidase-A Dimer Compositions and Methods of Use
Application:
62/744,069 →
Disulfide Bond Stabilized Polypeptide Compositions and Methods of Use
Recombinant CDKL5 Proteins, Gene Therapy and Production Methods
Application:
17/773,416 →
Publication:
US US20230043046A1
Recombinant CDKL5 Proteins, Gene Therapy and Production Methods
Application:
62/928,134 →
Recombinant CDKL5 Proteins, Gene Therapy and Production Methods
Application:
62/928,140 →
Recombinant CDKL5 Proteins, Gene Therapy and Production Methods
Application:
63/090,520 →
Methods of Reducing Cerebrovascular Events in Patients with Fabry Disease
Application:
62/795,524 →
Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
Application:
62/801,355 →
Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
Application:
62/908,869 →
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
62/883,756 →
Method For Capturing And Purification Of Biologics
Application:
17/640,456 →
Publication:
US US20230220320A1
Method for Capturing and Purification of Recombinant Proteins
Application:
62/897,018 →
Variant IGF2 Constructs
Application:
17/767,803 →
Publication:
US US20240091321A1
Gene Therapy Vectors Variant IGF2 Peptide Fusions and Methods of Use
Application:
62/913,677 →
Variant IGF2 Constructs
Application:
62/929,054 →
Determination Of Gene Transduction Potency In Neuron-Like Cells
Application:
63/230,919 →
Vesicle Targeting Proteins And Uses Of Same
Application:
18/040,866 →
Publication:
US US20240043494A1
Vesicle Targeting Proteins And Uses Of Same
Application:
63/062,844 →
Vesicle Targeting Proteins And Uses Of Same
Application:
63/160,215 →
Adeno-Associated Virus Delivery of CLN3 Polynucleotide
Application:
63/146,110 →
Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
Application:
63/162,683 →
TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
Application:
16/314,145 →
Publication:
US US20210268072A1
TATk-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
Application:
62/355,579 →
TATk-CDKL5 Fusion Proteins, Compositions, Formulations, And Use Thereof
Application:
62/381,886 →
Neurotensin Variants and Tagged Proteins Comprising Neurotensin or Sortilin Propeptide
Application:
63/217,500 →
Adeno-Associated Virus Delivery of CLN3 Polynucleotide
Application:
63/248,756 →
Biomarkers For Lysosomal Storage Diseases
Application:
63/253,749 →
Compositions and Methods for Treating Mucopolysaccharidosis Iiia
Application:
63/278,626 →
TATk-CDKL5 FUSION PROTEINS, COMPOSITONS, FORMULATIONS, AND THEIR METHODS OF MAKING AND METHODS OF USING
Application:
61/946,280 →
Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
Application:
10/988,427 →
Publication:
US US20050137223A1
Hydroxy Piperidine Derivatives to Treat Gaucher Disease
Application:
12/756,382 →
Publication:
US US20100189708A1
Hydroxy piperidine derivatives to treat gaucher disease
Application:
60/519,496 →
Method of stabilizing triflated imino sugars
Application:
60/689,131 →
Stabilization of triflated compounds
Application:
11/449,529 →
Publication:
US US20060293508A1
Crystalline pivaloyl furanoses and methods of purification
Application:
60/689,119 →
Crystalline sugar compositions and method of making
Application:
11/449,515 →
Publication:
US US20060293250A1
Purification of imino sugars
Application:
60/689,130 →
Imino and Amino Sugar Purification
Treatment of CNS disorders associated with mutations in the acid beta-glucosidase gene
Application:
60/689,120 →
Tartrate salt of isofagomine and methods of use
Application:
60/808,020 →
Tartrate Salt Of Isofagomine And Methods Of Use
Application:
60/890,719 →
Use of Substrates as Pharmacological Chaperones
Application:
60/911,710 →
Use of Substrates as Pharmacological Chaperones
Application:
12/595,081 →
Publication:
US US20100197018A1
Treatment of Gaucher Disease with Specific Pharmacological Chaperones and Monitoring Treatment Using Surrogate Markers
Application:
60/911,699 →
Treatment of Gaucher Disease with Specific Pharmacological Chaperones and Monitoring Treatment Using Surrogate Markers
Application:
61/028,123 →
Treatment of Gaucher Disease with Specific Pharmacological Chaperones and Monitoring Treatment Using Surrogate Markers
Therapy Regimens, Dosing Regimens and Stable Medicaments for the Treatment of Pompe Disease
Application:
61/113,470 →
Therapy Regimens, Dosing Regimens and Stable Medicaments for the Treatment of Pompe Disease
Application:
12/616,670 →
Publication:
US US20100119502A1
Therapy Regimens, Dosing Regimens And Stable Medicaments For The Treatment Of Pompe Disease
Application:
13/105,720 →
Publication:
US US20110268721A1
Method for the treatment of neurological disorders by enhancing the activity of glucocerebrosidase
Application:
60/815,952 →
Periodic Acid-Schiff Staining with Detection in the Infrared Range
Application:
60/911,688 →
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Application:
60/914,288 →
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Application:
61/028,105 →
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Application:
61/014,744 →
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Application:
14/713,821 →
Publication:
US US20150352093A1
New Method for Preparing Isofagomine and Its Derivatives
Application:
12/601,176 →
Pharmacological Chaperones for the Treatment of Alzheimers Disease
Application:
61/222,207 →
Pharmacological chaperones for the treatment of Alzheimer's disease
Application:
61/077,772 →
Transmission Mount
Application:
60/957,200 →
Topical devices and methods for support of perineal tissues
Application:
61/133,744 →
Assays for Diagnosing and Evaluating Treatment Options for Pompe Disease
Application:
61/035,866 →
Assays for Diagnosing and Evaluating Treatment Options for Pompe Disease
Application:
12/920,856 →
Publication:
US US20110136151A1
Treatment of Pomper Disease with Specific Pharmacological Chaperones and Monitoring Treatment Using Surrogate Markers
Application:
61/035,869 →
TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS
Application:
12/920,864 →
Publication:
US US20110189710A1
Mouse Model for Pompe Disease and Methods of Use Thereof
Application:
61/153,533 →
Methods for Preventing and/or Treating Lysosomal Storage Disorders
Application:
61/168,109 →
Methods for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Application:
61/168,101 →
Multiple Compartment Dosing Model
Application:
61/108,192 →
Method for Treating Alzheimer's Disease Using Pharmacological Chaperones to Increase the Activity of Gangliosidases
Application:
61/252,799 →
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Application:
61/252,806 →
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Application:
16/049,203 →
Publication:
US US20180334432A1
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Application:
61/252,803 →
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Application:
15/217,217 →
Publication:
US US20160326114A1
Method of Treating Alzheimer's Disease Using Pharmacological Chaperones to Increase Presenilin Function and Gamma-Secretase Activity
Application:
61/331,735 →
Method of Treating Alzheimer's Disease Using Pharmacological Chaperones to Increase Presenilin Function and Gamma-Secretase Activity
Application:
13/696,000 →
Publication:
US US20130102538A1
Method for Diagnosing Pompe Disease
Application:
61/153,506 →
Method for Diagnosing Pompe Disease
Application:
13/212,917 →
Publication:
US US20120083010A1
Compounds and Methods for Treating or Preventing Disease Conditions Associated with Alpha-1-Antitrypsin
Application:
61/393,181 →
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System and/or Lysosomal Storage Disorders
Application:
62/489,621 →
Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders
Quantitation of GL3 in Human Urine
Application:
61/483,421 →
Quantitation of GL3 in Urine
Application:
13/464,660 →
Publication:
US US20120283290A1
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Application:
61/616,159 →
Alpha-Galactosidase a and 1-Deoxygalactonojirimycin Co-Formulation for the Treatment of Fabry Disease
Application:
61/672,566 →
Stable Parenteral DNJ Compositions
Application:
61/750,677 →
Stable Parenteral Dnj Compositions
Application:
61/914,839 →
Dosing Regimens for Treating and/or Preventing Cerebral Amyloidoses
Application:
61/979,408 →
Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
Application:
15/619,785 →
Publication:
US US20170273996A1
Variant, Recombinant Beta-Glucocerebrosidase Proteins with Increased Stability and Increased Retained Catalytic Activity
Application:
61/411,331 →
Novel Signal Sequences to Improve Protein Expressions and Secretion of Recombinant Enzymes and Other Proteins
Application:
61/415,926 →
Methods For Coupling Targeting Peptides Onto Recombinant Lysosomal Enzymes For Improved Treatments Of Lysosomal Storage Diseases
Application:
61/729,857 →
Methods For Coupling Targeting Peptides onto Recombinant Lysosomal Enzymes for Improved Treatments of Lysosomal Storage Diseases
Application:
61/490,957 →
Chemical Crosslinkers
Application:
61/794,784 →
Sugar Derivatives Comprising Sulfur-Containing Moieties And Methods Of Making Same
Application:
61/938,924 →
Sugar Derivatives Comprising Sulfur-Containing Moieties And Methods Of Making Same And Methods Of Using The Same For The Treatment Of MPS IIIC
Application:
15/461,577 →
Publication:
US US20170190665A1
Novel Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy
Application:
62/266,760 →
Regimens For Treating And Preventing Lysosomal Disorders And Degenerative Disorders Of The Central Nervous System
Application:
62/212,291 →
Oil-In-Water Emulsion with Improved Stability
Patent:
6,281,236 →
Application:
09/360,095 →
Methods for Treatment of Inflammatory Diseases
Allantoin-Containing Skin Cream
Application:
14/804,227 →
Publication:
US US20160095806A1
Allantoin-containing skin cream
Patent:
6,329,413 →
Application:
09/570,266 →
Flexible Applicator for Applying Oil-in-Water Emulsion with Improved Stability
Methods for Treatment of Inflammatory Diseases
Allantoin-Containing Skin Cream
Allantoin-Containing Skin Cream
Allantoin-Containing Skin Cream
Allantoin-Containing Skin Cream
Allantoin-Containing Skin Cream
Compositions and Methods of Treatment of Inflammatory Skin Conditions Using Allantoin
Application:
61/300,627 →
Methods of Treating Psoriasis Using Allantoin
Compositions and Methods of Treatment of Inflammatory Skin Conditions Using Allantoin
Application:
14/147,425 →
Publication:
US US20140194482A1
Compositions and Methods of Treatment of Inflammatory Skin Conditions Using Allantoin
Application:
14/223,183 →
Publication:
US US20140288137A1
Methods of Treating Psoriasis Using Allantoin
Compositions And Methods Of Treatment Of Inflammatory Skin Conditions Using Allantoin
Application:
15/090,398 →
Publication:
US US20160213649A1
Compositions and Methods of Treatment of Inflammatory Skin Conditions Using Allantoin
Application:
15/165,967 →
Publication:
US US20170105967A1
Compositions and Methods for Treatment of Inflammatory Skin Conditions Using Allantoin
Application:
15/390,248 →
Publication:
US US20170105968A1
Keloid Reduction Using Topical Allantoin
Application:
61/921,231 →
Keloid Reduction Using Topical Allantoin
Application:
15/108,200 →
Publication:
US US20160338997A1
Methods for Treating Burns Using Allantoin
Application:
61/940,069 →
Methods for Treating Burns Using Allantoin
Application:
15/118,782 →
Publication:
US US20170049749A1
Allantoin-containing preparations for administration as gels
Application:
60/341,906 →
Allantoin-containing preparations for administration as aerosols
Application:
60/349,147 →
Methods of Treating Epidermolysis Bullosa
Application:
62/558,260 →
Methods of Treating Epidermolysis Bullosa
Application:
62/663,896 →
Methods of Treating Epidermolysis Bullosa
Application:
62/676,210 →
Methods of Treating Skin Lesions
Application:
62/593,745 →
Methods of Treating Skin Lesions
Application:
62/663,937 →
Methods of Treating Skin Lesions
Application:
62/676,212 →
Methods of Treating Pyogenic Granulomas
Application:
62/611,650 →
Assays for Diagnosing and Evaluating Treatment Options for Fabry Disease
Methods For Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Patent:
48,608 →
Application:
16/222,305 →
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Use of Migalastat for Treating Fabry Disease in Pregnant Patients
Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
Highly Purified Batches of Pharmaceutical Grade 1-Deoxygalactonojirimycin Compounds
Drug Package
Patent:
843,850 →
Application:
29/585,388 →
Drug Package
Patent:
877,625 →
Application:
29/605,763 →
Drug Package
Patent:
867,162 →
Application:
29/684,830 →
Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives
Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Method for Selection of High M6P Recombinant Proteins
Method for Selection of High M6P Recombinant Proteins
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Gene Therapy Constructs and Methods of Use
Gene Therapy Constructs and Methods of Use
Disulfide Bond Stabilized Polypeptide Compositions and Methods of Use
Treatment of CDKL5 Disorders with GSK3B Inhibitor Tideglusib
TATk-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
TATk-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
Tatk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
TATk-CDKL5 Fusion Proteins, Compositions, Formulations, And Use Thereof
Pharmacological Chaperones for Treating Obesity
Pharmacological Chaperones for Treating Obesity
Tartrate Salt of Isofagomine and Methods of Use
Periodic Acid-Schiff Staining with Detection in the Infrared Range
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Mouse Model for Pompe Disease and Methods of Use Thereof
Methods for Preventing and/or Treating Lysosomal Storage Disorders
Methods for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Multiple Compartment Dosing Model
Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases
Method for Treating Cerebral Amyloid Angiopathy Using Pharmacological Chaperones to Increase the Activity of Gangliosidases
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System
Compounds and Methods for Treating or Preventing Disease Conditions Associated with Alpha-1-Antitrypsin
Compounds and Methods for Treating or Preventing Disease Conditions Associated with Alpha-1-Antitrypsin
Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Alpha-Galactosidase a and 1-Deoxygalactonojirimycin Co-Formulation
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation For The Treatment of Fabry Disease
Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease
Stable Parenteral Dnj Compositions
Stable Parenteral DNJ Compositions
Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
Novel Signal Sequences to Improve Protein Expressions and Secretion of Recombinant Enzymes and Other Proteins
Methods for Coupling Targeting Peptides Onto Recombinant Lysosomal Enzymes for Improved Treatments of Lysosomal Storage Diseases
Methods for Coupling Targeting Peptides Onto Recombinant Lysosomal Enzymes for Improved Treatments of Lysosomal Storage Diseases
Chemical Crosslinkers
Chemical Crosslinkers
Sugar Derivatives Comprising Sulfur-Containing Moieties and Methods of Making Same and Methods of Using the Same for the Treatment of Mps Iiic
Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy
Novel Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy
Compounds and Methods for the Treatment of Alzheimer's Disease and/or Cerebral Amyloid Angiopathy
Regimens For Treating And Preventing Lysosomal Disorders And Degenerative Disorders Of The Central Nervous System
Related Assignments
(14)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Nov 19, 2013
From: GREENE, DOUGLAS STUART; VALENZANO, KENNETH JOSEPH
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 031634/0285 →
Assignment of Assignor's Interest
Jul 11, 2016
From: BENJAMIN, ELFRIDA
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 039120/0076 →
Assignment of Assignor's Interest
Mar 8, 2018
From: BENJAMIN, ELFRIDA
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 045144/0079 →
Security Interest
Sep 28, 2018
From: AMICUS THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 047004/0208 →
Assignment of Assignor's Interest
Nov 5, 2019
From: LO PRETE, JEFFREY; MUSTUFA, MUZAMMIL; GERSHKOWITZ, JAYNE
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 050916/0228 →
Security Interest
May 11, 2020
From: AMICUS THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 052625/0916 →
Omnibus Confirmation of Assignment Agreement
May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
Security Interest
Jul 30, 2020
From: AMICUS THERAPEUTICS, INC.
To: HAYFIN SERVICES LLP, AS AGENT
Reel/Frame 053365/0342 →
Release of Security Interest
Jul 30, 2020
From: BPCR LIMITED PARTNERSHIP
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 053360/0659 →
Assignment of Assignor's Interest
May 10, 2022
From: GOTSCHALL, RUSSELL
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 059879/0309 →
Release of Security Interest
Oct 6, 2023
From: HAYFIN SERVICES LLP
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 065164/0945 →
Assignment of Assignor's Interest
Jul 11, 2024
From: CASTELLI, JEFF
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 067959/0418 →
Security Interest
Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
Release of Security Interest
Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →